Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2020 from OUS - Section of Preventive Medicine
47 publications found
Markers of remodeling in subcutaneous adipose tissue are strongly associated with overweight and insulin sensitivity in healthy non-obese men
Sci Rep, 10 (1), 14055
DOI 10.1038/s41598-020-71109-4, PubMed 32820223
Physical activity and the risk of heart failure: a systematic review and dose-response meta-analysis of prospective studies
Eur J Epidemiol (in press)
DOI 10.15420/cfr.2016:25:2, PubMed 33331992
The randomised Oslo study of renal denervation vs. Antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up
Blood Press
DOI 10.1080/08037051.2020.1828818, PubMed 33030064
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
JAMA Cardiol, 5 (6), 709-713
DOI 10.1001/jamacardio.2020.0728, PubMed 32347887
Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension
Blood Press
DOI 10.1080/08037051.2020.1789446, PubMed 32633141
Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction
J Clin Lipidol, 14 (3), 339-345
DOI 10.1016/j.jacl.2020.04.002, PubMed 32418822
Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?
J Hypertens, 38 (8), 1396-1406
DOI 10.1097/HJH.0000000000002532, PubMed 32618895
Dose-response relationship between hand-arm vibration exposure and vibrotactile thresholds among roadworkers
Occup Environ Med, 77 (3), 188-193
DOI 10.1136/oemed-2019-105926, PubMed 31919277
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
JAMA Cardiol (in press)
DOI 10.1001/jamacardio.2020.3151, PubMed 32785614
Delirium in patients with hip fracture is associated with increased heart rate variability
Aging Clin Exp Res, 32 (11), 2311-2318
DOI 10.1007/s40520-019-01447-5, PubMed 31916197
Cardiovascular risk factors and body composition in adults with achondroplasia
Genet Med
DOI 10.1038/s41436-020-01024-6, PubMed 33204020
Beneficial effect on serum cholesterol levels, but not glycaemic regulation, after replacing SFA with PUFA for 3 d: a randomised crossover trial
Br J Nutr, 1-11 (in press)
DOI 10.1017/S0007114520003402, PubMed 32873354
Cognition After Lowering LDL-Cholesterol With Evolocumab
J Am Coll Cardiol, 75 (18), 2283-2293
DOI 10.1016/j.jacc.2020.03.039, PubMed 32381158
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial
JAMA Cardiol, 5 (8), 952-957
DOI 10.1001/jamacardio.2020.0882, PubMed 32432684
Ventilatory support for hypoxaemic intensive care patients with COVID-19
Tidsskr Nor Laegeforen, 140 (11)
DOI 10.4045/tidsskr.20.0445, PubMed 32815344
Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers
J Clin Lipidol (in press)
DOI 10.1016/j.jacl.2020.12.006, PubMed 33358307
Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
Scand Cardiovasc J, 54 (5), 274-279
DOI 10.1080/14017431.2020.1775878, PubMed 32500743
Comprehensive lipid and metabolite profiling in healthy adults with low and high consumption of fatty fish: a cross-sectional study
Br J Nutr, 1-9 (in press)
DOI 10.1017/S0007114520002305, PubMed 32594945
Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study
Open Heart, 7 (2)
DOI 10.1136/openhrt-2020-001296, PubMed 32719074
Risk of cardiovascular disease after preventive salpingo-oophorectomy
Int J Gynecol Cancer, 30 (5), 575-582
DOI 10.1136/ijgc-2019-000856, PubMed 32332121
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
Cardiovasc Drugs Ther, 34 (4), 515-523
DOI 10.1007/s10557-020-06984-0, PubMed 32363493
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®
Diab Vasc Dis Res, 17 (6), 1479164120975256
DOI 10.1177/1479164120975256, PubMed 33307785
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Eur Heart J, 41 (1), 111-188
DOI 10.1093/eurheartj/ehz455, PubMed 31504418
Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies
Eur Heart J, 41 (16), 1588-1599
DOI 10.1093/eurheartj/ehaa121, PubMed 32211888
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Circulation, 141 (20), 1600-1607
DOI 10.1161/CIRCULATIONAHA.120.046397, PubMed 32223429
Ten-Year Prediction of cardiovascular disease in healthy Norwegian men based on NORRISK-2
Tidsskr. Nor. Laegeforen., 140 (12), 1240-1246
Tiårsprediksjon av hjerte- og karsykdom hos friske norske menn basert på NORRISK-2
Tidsskr Nor Laegeforen, 140 (12)
DOI 10.4045/tidsskr.20.0089, PubMed 32900157
Nutritional challenges in children and adolescents with Down syndrome
Lancet Child Adolesc Health, 4 (6), 455-464
DOI 10.1016/S2352-4642(19)30400-6, PubMed 32450124
Lecithin:cholesterol acyltransferase: symposium on 50 years of biomedical research from its discovery to latest findings
J Lipid Res, 61 (8), 1142-1149
DOI 10.1194/jlr.S120000720, PubMed 32482717
On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy
Blood Press, 29 (5), 319-326
DOI 10.1080/08037051.2020.1782171, PubMed 32586143
Effects of dietary methionine and cysteine restriction on plasma biomarkers, serum fibroblast growth factor 21, and adipose tissue gene expression in women with overweight or obesity: a double-blind randomized controlled pilot study
J Transl Med, 18 (1), 122
DOI 10.1186/s12967-020-02288-x, PubMed 32160926
Validation of the cardiovascular risk model NORRISK 2 in South Asians and people with diabetes
Scand Cardiovasc J
DOI 10.1080/14017431.2020.1821909, PubMed 33073627
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action
JAMA Cardiol, 5 (2), 217-229
DOI 10.1001/jamacardio.2019.5173, PubMed 31895433
Factors influencing the opportunities of supporting staff to promote a healthy diet in adults with intellectual disabilities
J Appl Res Intellect Disabil
DOI 10.1111/jar.12846, PubMed 33274594
Familial hypercholesterolaemia: history, diagnosis, screening, management and challenges
Heart, 106 (24), 1940-1946
DOI 10.1136/heartjnl-2019-316276, PubMed 32933999
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
Eur J Prev Cardiol, 2047487320902750
DOI 10.1177/2047487320902750, PubMed 32019364
Evaluating the use of the heart age tool in community pharmacies: a 4-week cluster-randomized controlled trial
Eur J Public Health, 30 (6), 1139-1145
DOI 10.1093/eurpub/ckaa048, PubMed 32206810
2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia
Atherosclerosis, 319, 28-34 (in press)
DOI 10.1016/j.atherosclerosis.2020.12.019, PubMed 33465659
Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia
Atherosclerosis, 316, 48-52
DOI 10.1016/j.atherosclerosis.2020.11.027, PubMed 33302044
Fatty acid profile and estimated desaturase activities in whole blood are associated with metabolic health
Lipids Health Dis, 19 (1), 102
DOI 10.1186/s12944-020-01282-y, PubMed 32438926
A comprehensive metabolic profiling of the metabolically healthy obesity phenotype
Lipids Health Dis, 19 (1), 90
DOI 10.1186/s12944-020-01273-z, PubMed 32386512
Cardiovascular Risk Factors are Inversely Associated With Omega-3 Polyunsaturated Fatty Acid Plasma Levels in Pediatric Kidney Transplant Recipients
J Ren Nutr (in press)
DOI 10.1053/j.jrn.2020.06.002, PubMed 32792219
Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations
Curr Med Res Opin, 36 (5), 713-730
DOI 10.1080/03007995.2020.1729708, PubMed 32050807
Differential associations of cardiac troponin T and cardiac troponin I with coronary artery pathology and dynamics in response to short-duration exercise
Clin Biochem (in press)
DOI 10.1016/j.clinbiochem.2020.11.005, PubMed 33245871
Upregulation of HLA Class I and Antiviral Tissue Responses in Hashimoto's Thyroiditis
Thyroid, 30 (3), 432-442
DOI 10.1089/thy.2019.0607, PubMed 31910110
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients
Circulation, 142 (7), 621-642
DOI 10.1161/CIRCULATIONAHA.120.046361, PubMed 32546049
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial
JAMA Cardiol, 5 (7), 787-793
DOI 10.1001/jamacardio.2020.0764, PubMed 32347885